Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metal-On-Metal Hips Get Failing Grade In New Registry Analysis

This article was originally published in The Gray Sheet

Executive Summary

Devices were linked to a notably higher five-year revision rate compared to metal-on-polyethylene or ceramic-on-ceramic hips in an analysis of more than 400,000 implants. Recalled J&J/DePuy ASR devices were not included in the analysis.

You may also be interested in...



FDA Looks To Lead World In Post-Market Device Surveillance With Safety Plan, Investments

US FDA Nov. 20 announced plans for a broad series of updates to its Medical Device Safety Action Plan for the next several months, with the goal that FDA "is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.

J&J Ordered To Pay $502 Million In Hip Suit

This is the first win for patients and the second case to go to trial of more than 7,000 complaints against DePuy Orthopedics filed nationwide alleging the metal-on-metal version of the Pinnacle artificial hip broke prematurely and required resurfacing.

PMAs Are The New Reality For Metal-On-Metal Hips

A final order from FDA calls for manufacturers to submit PMAs or take their metal-on-metal hip devices off the market by May 18. The widely anticipated move is part of a broader response to elevated adverse event rates tied to the products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel